FR2901479B1 - IMMUNE RESPONSE AGAINST COVALENTLY MODIFIED PEPTIDES THAT MODIFY INTERACTIONS OF PHOSPHATIDYLINOSITOL PHOSPHATES AND CALMODULIN IN A LIVING ORGANISM - Google Patents

IMMUNE RESPONSE AGAINST COVALENTLY MODIFIED PEPTIDES THAT MODIFY INTERACTIONS OF PHOSPHATIDYLINOSITOL PHOSPHATES AND CALMODULIN IN A LIVING ORGANISM

Info

Publication number
FR2901479B1
FR2901479B1 FR0604671A FR0604671A FR2901479B1 FR 2901479 B1 FR2901479 B1 FR 2901479B1 FR 0604671 A FR0604671 A FR 0604671A FR 0604671 A FR0604671 A FR 0604671A FR 2901479 B1 FR2901479 B1 FR 2901479B1
Authority
FR
France
Prior art keywords
calmodulin
immune response
response against
living organism
modified peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0604671A
Other languages
French (fr)
Other versions
FR2901479A1 (en
Inventor
Halina Zofia Malina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0604671A priority Critical patent/FR2901479B1/en
Publication of FR2901479A1 publication Critical patent/FR2901479A1/en
Application granted granted Critical
Publication of FR2901479B1 publication Critical patent/FR2901479B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0604671A 2006-05-24 2006-05-24 IMMUNE RESPONSE AGAINST COVALENTLY MODIFIED PEPTIDES THAT MODIFY INTERACTIONS OF PHOSPHATIDYLINOSITOL PHOSPHATES AND CALMODULIN IN A LIVING ORGANISM Expired - Fee Related FR2901479B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0604671A FR2901479B1 (en) 2006-05-24 2006-05-24 IMMUNE RESPONSE AGAINST COVALENTLY MODIFIED PEPTIDES THAT MODIFY INTERACTIONS OF PHOSPHATIDYLINOSITOL PHOSPHATES AND CALMODULIN IN A LIVING ORGANISM

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0604671A FR2901479B1 (en) 2006-05-24 2006-05-24 IMMUNE RESPONSE AGAINST COVALENTLY MODIFIED PEPTIDES THAT MODIFY INTERACTIONS OF PHOSPHATIDYLINOSITOL PHOSPHATES AND CALMODULIN IN A LIVING ORGANISM

Publications (2)

Publication Number Publication Date
FR2901479A1 FR2901479A1 (en) 2007-11-30
FR2901479B1 true FR2901479B1 (en) 2009-09-04

Family

ID=38093362

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0604671A Expired - Fee Related FR2901479B1 (en) 2006-05-24 2006-05-24 IMMUNE RESPONSE AGAINST COVALENTLY MODIFIED PEPTIDES THAT MODIFY INTERACTIONS OF PHOSPHATIDYLINOSITOL PHOSPHATES AND CALMODULIN IN A LIVING ORGANISM

Country Status (1)

Country Link
FR (1) FR2901479B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922769A1 (en) * 2007-10-31 2009-05-01 Halina Malina Preparation of compound, useful to cause immune reactions to prevent e.g. degenerative diseases, cancers, and Parkinson's diseases, where the compound is product of peptides corresponding to intrinsically disordered sequences

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791263B1 (en) * 1999-03-26 2001-04-27 Halina Zofia Malina DRUG PREPARATIONS BASED ON AN IMMUNE RESPONSE AGAINST ACCUMULATION OF XANTHURENIC ACID MODIFIED PROTEINS

Also Published As

Publication number Publication date
FR2901479A1 (en) 2007-11-30

Similar Documents

Publication Publication Date Title
EP2097540A4 (en) Genemap of the human genes associated with crohn's disease
EP1883708A4 (en) Genemap of the human genes associated with crohn's disease
IL238798A0 (en) A ca6 antigen specific cytotoxic conjugate and methods of usinng the same
PL2650020T3 (en) Trimeric OX40-immunoglobulin fusion protein and methods of use
WO2008076883A3 (en) Triazine derivatives and their therapeutical applications
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
GB2440418B (en) Seismic source and source array having depth-control and steering capacity
PL2532679T3 (en) Human antibodies against il13 and therapeutic uses
EP2164425A4 (en) Nanostructure surface coated medical implants and methods of using the same
EP1780276A4 (en) Bone/joint disease sensitivity gene and use thereof
IL177889A0 (en) Methods and devices for non-invasively measuring quantitative information of substances in living organisms
PT1851315E (en) Human antibodies against rabies and uses thereof
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2059806A4 (en) Modified annexin proteins and methods for their use in platelet storage and transfusion
IL191064A0 (en) Real time nucleic acid detection in vivo using protein complementation
ZA200907326B (en) Microemulsions and their use for improving the biological efficacy of pesticides
WO2009070234A3 (en) Complexation of fatty acid-conjugated molecules with albumin
AU307790S (en) Toner cartridge
IL212215A0 (en) Use of lipid conjugates in the treatment of disease
PL1890692T3 (en) Formulations of lipoic acid and the benzyl ester of hyaluronic acid in the pharmaceutical and cosmetic fields
FR2901479B1 (en) IMMUNE RESPONSE AGAINST COVALENTLY MODIFIED PEPTIDES THAT MODIFY INTERACTIONS OF PHOSPHATIDYLINOSITOL PHOSPHATES AND CALMODULIN IN A LIVING ORGANISM
EP1932496A4 (en) Stent to be placed in the living body
USD578915S1 (en) Body composition meter
EP1799851A4 (en) Methods of diagnosis or detection using three-dimensional analysis
CA115985S (en) Apparatus for stuffing plush toys

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20180131